Date & Time
Location
The Franklin Institute
222 N 20th St
Philadelphia, PA 19103
Registration Information
This event is complimentary but pre-registration is required. A virtual option is available for this event, please indicate if you are signing up for in-person or virtual when you register.
Schedule
Program: 8:30 AM - 5:30 PM
Reception: 5:30 PM - 7:00 PM
8:00 AM | Registration & Light Breakfast |
8:50 – 9:00 AM | Welcome by Johnathan Whetstine, PhD |
9:00 – 9:25 AM | Daniel De Carvalho, PhD – University of Toronto |
9:25 – 9:50 AM | Chuan He, PhD – University of Chicago |
9:50 – 10:15 AM | Karen Adelman, PhD – Harvard Medical School |
10:15 – 10:20 AM | Keynote Introduction |
10:20 – 11:05 AM | Robert Roeder, PhD - The Rockerfeller University |
11:05 – 11:25 AM | Break |
11:25 – 11:50 AM | Gerd Blobel, MD, PhD – Children’s Hospital of Philadelphia |
11:50 AM – 12:15 PM | Nada Jabado, MD, PhD – McGill University |
12:15 – 2:00 PM | Lunch/Poster Session |
2:00 – 2:25 PM | Jian Jin, PhD – Icahn School of Medicine at Mount Sinai |
2:25 – 2:50 PM | Yael David, PhD – Memorial Sloan Kettering Cancer Center |
2:50 – 4:10 PM | Industry Panel – Epigenetic Therapeutic Opportunities |
4:10 – 4:30 PM | Break |
4:30 – 4:55 PM | Scott Armstrong, MD, PhD – Dana-Farber Cancer Institute, Harvard |
4:55 – 5:20 PM | Anjana Rao, PhD – La Jolla Institute for Immunology |
5:20 – 5:30 PM | Closing Remarks |
Speakers
Keynote Speaker: Dr. Robert G. Roeder, The Rockefeller University
- Dr. Daniel De Carvalho, University of Toronto
- Dr. Chuan He, University of Chicago
- Dr. Karen Adelman, Harvard Medical School
- Dr. Gerd Blobel, Children’s Hospital of Philadelphia
- Dr. Nada Jabado, McGill University
- Dr. Jian Jin, Icahn School of Medicine at Mount Sinai
- Dr. Yael David, Memorial Sloan Kettering Cancer Center
- Dr. Scott Armstrong, Dana-Farber Cancer Institute, Harvard
- Dr. Anjana Rao, La Jolla Institute for Immunology
The event will also feature an afternoon speaker session with leading industry members discussing epigenetic-related therapies. Panelists include:
- AstraZeneca
- Daiichi Sankyo
- Epizyme
- Foghorn Therapeutics – “Targeting Transcription Factor-BAF interactions in Cancer” - Asad Taherbhoy, PhD
- Incyte - "Targeting BET Bromodomain Proteins for the Treatment of Cancer" - Susan Wee, PhD
- Oryzon Genomics - “Iadademstat, paving the way to new therapies in AML and SCLC” - Ana Limón, PhD
- Vyne Therapeutics
Thank You to Our Sponsors!
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|